Indegene Ltd Reports FY26 Results, Recommends Final Dividend

Consolidated Total Income ₹35,825 million (₹3,582.50 cr); Consolidated Profit After Tax ₹4,011 million (₹401.10 cr).

Financial Results Announced

Indegene Limited's Board of Directors met on April 29, 2026, to approve the audited financial results for the fiscal year ending March 31, 2026. The company reported consolidated total income of ₹35,825 million (₹3,582.50 crore) and consolidated profit after tax (PAT) of ₹4,011 million (₹401.10 crore). The board recommended a final dividend of ₹2.25 per equity share, which requires shareholder approval at the upcoming Annual General Meeting (AGM). The board also approved updates to several SEBI-related policies, covering areas such as material subsidiaries, whistleblowing, insider trading, related party transactions, and board evaluation. Additionally, shares were approved for allotment under the ESOP Scheme 2020 and RSU Scheme 2020.

What the Results Mean

The company's financial performance highlights its growth within the life sciences sector. The proposed dividend indicates a commitment to returning value to shareholders. The policy updates help maintain compliance and strengthen corporate governance.

Financial Performance History

Indegene has demonstrated consistent financial growth. For fiscal year 2025, the company reported a consolidated PAT of ₹3,232 million on total income of ₹32,323 million. In FY24, consolidated PAT was ₹2,469 million on total income of ₹2,469 million, showing an expanding revenue and profitability.

Impact of Decisions

Shareholders stand to receive a final dividend of ₹2.25 per equity share, subject to AGM approval. The updated SEBI policies will guide company operations, enhancing transparency and compliance. New shares issued under employee stock and RSU schemes will be allotted.

Potential Risks

Indegene Inc., a subsidiary, is facing a TCPA class action lawsuit in the United States. The company has set aside a provision of ₹203 million as an estimated settlement. Separately, a draft transfer pricing order for AY 2023-24 proposed adjustments of ₹1,114 million. This is being addressed through the Mutual Agreement Procedure (MAP) and is noted as a contingent liability.

Competitive Landscape

Indegene operates in specialized digital transformation services for complex industries. Competitors like Persistent Systems and LTIMindtree offer similar digital transformation capabilities. Indegene differentiates itself with its specific focus on the life sciences sector.

Looking Ahead

Investors will watch for shareholder approval of the final dividend at the upcoming AGM, along with the announcement of the record date. Progress in resolving the US TCPA lawsuit and the transfer pricing order will also be key.